Das Medizinportal     Aktuelles für medizinische Fachkreise
Menü

Das Medizinportal     Aktuelles für medizinische Fachkreise

Literatur:

Moderne Therapiekonzepte beim Kolonkarzinom – personalisierte Therapie

Arndt Vogel und Martha M. Kirstein, Hannover (S. 10-15)

 

  1. Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist 2014;19:1156-1168.
  2. Rowland A, Dias MM, Wiese MD, Kichenadasse G, McKinnon RA, Karapetis CS, Sorich MJ. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015;112:1888-1894.
  3. Seligmann JF, Elliott F, Richman SD, Jacobs B, Hemmings G, Brown S, Barrett JH, et al. Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA Oncol 2016.
  4. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, et al. The ge-nomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015;526:263-267.
  5. von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014;140:1607-1614.
  6. Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol 2013;24:2554-2559.
  7. Heinemann V, Modest DP, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, et al. Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial. Journal of Clinical Oncology 2014;32.
  8. AP V, D N, F I. Impact of primary (1º) tumor location on overall survival (OS) and pro-gression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance). . J Clin Oncol 2016;34.
  9. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or af-ter first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015;16:499-508.
  10. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (COR-RECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-312.
  11. Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16:1306-1315.
  12. Simkens LH, van Tinteren H, May A, ten Tije AJ, Creemers GJ, Loosveld OJ, de Jongh FE, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015;385:1843-1852.
  13. Hegewisch-Becker S, Graeven U, Lerchenmuller CA, Killing B, Depenbusch R, Steffens CC, Al-Batran SE, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015;16:1355-1369.
  14. Ruers T, Punt CJA, van Coevorden F, Pierie JP, Rinkes IB, Ledermann JA, Poston GJ, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). Journal of Clinical Oncology 2015;33.
  15. van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2016;34:1723-1731.
  16. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015;372:2509-2520.
  17. Ebert PJ, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity 2016;44:609-621.
  18. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, Zagonel V, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016.
  19. Hong DS, Morris V, El Osta BE, Fu SQ, Overman MJ, Piha-Paul SA, Subbiah V, et al. Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in pa-tients with BRAF-mutated metastatic colorectal cancer and advanced cancers. Journal of Clinical Oncology 2015;33.

Chirurgie des Kolonkarzinoms – Was bringt die Umsetzung internationaler Stan-dards?

Stefan Berkhoff, Eva Hofmann, Thomas W. Kraus (S. 16-18)

 

  1. S3-Leitlinie Kolorektales Karzinom, Version 1.1 –2014, AWMF-Registernummer: 021/007OL (2014)
  2. E. Swart, C. Wolff, P. Klas, S. Deh und B.-P. Robra: Häufigkeit und kleinräumige Variabilität von Operationen, Chirurg (2000) 71: 109-114
  3. DGAV-StuDoQ: Studien-, Dokumentations- und Qualitätszentrum der Deutschen Gesell-schaft für Allgemein- und Viszeralchirurgie (DGAV). www.dgav.de/studoq/ueber-studoq.html
  4. W. van Gijn , C.B.M. van den Broek , P. Mroczkowski, A. Dziki , G. Romano, D. Pavalkis , M.W.J.M. Wouters , B. Møller , A. Wibe, L. Pahlman, H. Harling, J.J. Smith, F. Penninck , H. Ortiz, V. Valentini, C.J.H. van de Velde. The EURECCA project: Data items scored by Euro-pean colorectal canceraudit registries. EJSO 38 (2012):  467e471
  5. Th. Lehnert, A. Schaible, Ch. Herfarth: Onkologische Prinzipien beim Kolonkarzinom. Chi-rurg (1999): 499-510 
  6. J. Reibetanz, C.-T. Germer: Verlängerung des krankheitsfreien  Überlebens durch komplette  mesokolische Exzision  beim Kolonkarzinom. Chirurg (2015): 86:379
  7. Leitlinien- Clearingbericht 2005 - Clearingbericht „Kolorektales Karzinom“. äzq Schriften-reihe Band 22, ISBN 3-89906-913-7   /  ISSN 1611-4906 (2005)
  8. Kennzahlenauswertung 2014. Benchmarking-Bericht der zertifizierten Darmkrebszentren (onkozert), Kennzahlenjahr 2012 / Auditjahr 2013

Darmkrebs-Prävention: Möglichkeiten – Grenzen – Akzeptanz

Hermann Brenner (S. 19-21)

 

  1. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland (Hrsg.). Krebs in Deutschland 2009/2010. Robert Koch-Institut, Berlin 2013.
  2. Brenner H, Kloor M, Pox C. Colorectal cancer. Lancet 2014; 383:1490-502.
  3. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104-7.
  4. Hewitson P, Glasziou P, Watson E, et al. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. Am J Gastroenterol 2008;103;1541-9.
  5. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med 2013;369:1106-14.
  6. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur J Cancer 2013;49:3049-54.
  7. Lee JK, Liles EG, Bent S, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 2014;160:171.
  8. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut. 2010;59:62-8. 
  9. Beschluss   des Gemeinsamen Bundesausschusses über eine Änderung der Krebsfrüher-kennungsRichtlinie: Bewertung eines iFOBT-basierten Darmkrebsscreenings im Vergleich zu einem gFOBT-basierten Darmkrebsscreening. www.g-ba.de/downloads/39-261-2572/2016-04-21_KFE-RL_Bewertung-iFOBT.pdf, aufgerufen am 14.5.2016
  10. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;370;1287-97.
  11. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-33.
  12. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: Follow-up findings of the Italian Randomized Controlled Trial – SCORE. J Natl Cancer Inst 2011;103:1310-22. 
  13. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345-57. 
  14. Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014;312:606-15.
  15. Brenner H, Stock C, Hoffmeister M. Effect of  screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467.
  16. Brenner H, Chang-Claude J, Jansen L, et al. Reduced risk of colorectal cancer up to 10 years after screening surveillance or diagnostic colonoscopy. Gastroenterology 2014;146:709-17.
  17. Stock C, Pulte D, Haug U, et al. Subsite-specific colorectal cancer risk in the colorectal en-doscopy era. Gastrointest Endosc 2012; 75: 621-30.
  18. Brenner H, Schrotz-King P, Holleczek B, et al. Declining bowel cancer incidence and mortality in Germany - an analysis of time trends in the first ten years after the introduction of screening colonoscopy. Dtsch Ärztebl Int 2016;113:101-6.
  19. Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (GEKID). GEKID Atlas. www.gekid.de, aufgerufen am 14.5.2016. 
  20. Brenner H, Altenhofen L, Stock C, et al. Prevention, early detection, and overdiagnosis of colorectal cancer within 10 years of screening colonoscopy in Germany. Clin Gastroenterol Hepatol 2015;13:717-23. 

Liquid Biopsy beim Kolonkarzinom: Klinische Relevanz und Ausblick

Alexander Baraniskin, Wolff Schmiegel (S.22-24)

 

  1. Datenbank des Robert-Koch-Instituts
  2. Alberts SR: Update on the optimal management of patients with colorectal liver metastases. Crit Rev Oncol Hematol 2012 Oct;84(1):59-70
  3. Peeters et al, Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 32, 2014 (suppl 3; abstr LBA387)
  4. Gerlinger et al, Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N Engl J Med 2012; 366:883-892
  5. Inger Marie Løes et al, Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metas-tases. Int J Cancer. 2016 Mar 16. doi: 10.1002/ijc.30089. [Epub ahead of print]
  6. Dressmann et al, Transforming single DNA molecules into fluorescent magnetic parti-cles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22.
  7. Diehl F, et al Circulating mutant DNA to assess tumor dynamics. NatureMed 2008, 14: 985–990. 
  8. Schwarzenbach H, Dave S. B. Hoon & Klaus Pantel Cell-free nucleic acids as biomarkers in cancer patients Nature Reviews Cancer 11, 426-437 (June 2011)
  9. Bettegowda C et al, Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014; 6:224ra24
  10. Hahn S, et al. Eur J Cancer 2015;51(suppl 3):S79.
  11. Morelli et al, Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Annals of On-cology 26: 731–736, 2015 
  12. Siravegna et al, Clonal evolution and resistance to EGFR blockade in the blood of colo-rectal cancer patients. Nature Medicine  21, 795–801, 2015

Literatur Update: Diagnostik und Therapie des Multiplen Myeloms

Jutta Auberger & Christian Straka (S. 41-46)

 

  1. Ferlay J et al. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0 IARC Cancer Bace N0.5 Lyon, IARC Press, 2001.
  2. Greipp PR et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23 (15):3412-20.
  3. Palumbo A, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9.
  4. Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and man-agement. Am J Hematol.;87(1):78-88.
  5. Avet-Loiseau H, et al. Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience. J Clin Oncol. 2013;31(22):2806.
  6. Straka C, et al. The effects of induction chemotherapy and high-dose melphalan with tandem autologous transplantation in multiple myeloma: The prospective randomized DSMM2 study. ASH Annual Meeting Abstracts 2007; 110:446.
  7. Ballester G, et al. Hematopoietic stem cell transplantation in the elderly. Oncology (Willis-ton Park) 2007; PMID:18179047.
  8. Martinez-Lopez J, et al. Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 2011;118 (3):529-34.
  9. Cavo, M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalido-mide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376(9758):2075-85. 
  10. Mateos MV, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by mainte-nance. Blood. 2011;118(17):4547-53. 
  11. Knop S, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with re-lapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood. 113(18):4137-43. 
  12. Lokhorst HM, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115(6):1113-20. 
  13. Rosinol L, et al. Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease. Haematologica.2012;97(4):616-21. 
  14. Giralt S, et al. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009;23(10):1904-12.
  15. Kumar S, et al.  Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114(9):1729-35. 
  16. Saad, A, et al. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Mar-row Transplant. 2014;20(3):402-408.
  17. Barlogie B, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood. 1997;89(3):789-93.
  18. Attal M, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335(2):91-7.
  19. Child JA, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-83.
  20. Palumbo A, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104(10):3052-7. 
  21. Palumbo A, et al. Autologous transplantation and maintenance therapy in multiple mye-loma. N Engl J Med. 2014;371(10):895-905. 
  22. Gay F, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015;16(16):1617-29. 
  23. Cavo M, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25(17):2434-41.
  24. Naumann- Winter, F. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev. 2012;10:CD004626.
  25. Attal M, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495-502.
  26. Björkstrand, BB, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88(12):4711-8.
  27. Straka C, et al. Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM). American Society of Oncology (ASCO) Annual Meeting 2015. Abstract #8511. 
  28. Sonnevelt P, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J Clin Oncol. 2012;30(24):2946-55.
  29. Neben K, et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-8.
  30. Sacchi S, et al. A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autolgous stem cell transplant. Leuk Lymphoma. 2011;52(10):1942-8. 
  31. Fayers, PM, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood. 2011;118(5):1239-47.
  32. San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-17.
  33. San Miguel JF, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013;31(4):448-55.
  34. Morabito F, et al. Bortezomib, melphalan, prednisone (VMP) versus melphalan, predni-sone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retro-spective case-matched study. Am J Hematol. 2014;89(4):355-62. 
  35. San Miguel J, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-17.
  36. Auberger J, et al. Topical evening primrose oil for reduction of bortezomib-induced skin reactions. Ann Hematol. 2013;92(7):995-6. 
  37. Falco P, et al. Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. Leukemia. 2013;27(3):695-701
  38. Kristinsson SY, et al. Arterial and venous thrombosis in monoclonal gammopathy of unde-termined significance and multiple myeloma: a population-based study. Blood. 2010;115(24):4991-8.
  39. Mateos, MV, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalido-mide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-41.
  40. Palumbo A, et al. Continuous lenalidomide treatment for newly diagnosed multiple mye-loma. N Engl J Med. 2012;366(19):1759-69. 
  41. Mateos MV, et al. Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by mainte-nance. Blood. 2011;118(17):4547-53. 
  42. Sonneveld P, Goldschmidt H, Rosinol L et al.: Bortezomib-based versus non bortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, con-trolled trials. J Clin Oncol 2013:Jul 29 (Epub).
  43. Stewart AK, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142-52.
  44. Dimopoulos MA, et al. Carfilzomib and dexamethasone versus bortezomib and dexame-thasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a ran-domised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27-38.
  45. Moreau P, et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;374(17):1621-34.
  46. San Miguel J, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexa-methasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055.
  47. Leleu X, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.Blood. 2015;125(9):1411-7.
  48. Lonial S, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-60.
  49. Lonial S et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015;373(7):621-31.
  50. Richardson PG, et al. Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment. Blood. 2016;127(6):713-21.
  51. Golden EB, et al. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. Blood. 2009;113(23):5927-37. 
  52. Perrone G, et al. Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009;23(9):1679-86.

Pharmaforum - (Therapie der Patientin mit einem HER2-negativenmetastasiertenMammakarzinom) Optimaler Therapieerfolg mit Leitlinien-gerechtem Einsatz von Bevacizumab

Birgit-Kristin Pohlmann/ Mit freundlicher Unterstützung der Roche Pharma AG (S. 48-49)

  1. www.ago-online.de (AGO-Leitlinie zum Mammakarzinom, Version 2016.1)
  2. Gray R et al., JCO 2009, 20;27(30): 4966–4972.
  3. Roberts NJ et al., JCO 2011, 29(10): 1252–1260.
  4. Zielinski CC et al., ECC 2015, #1800.
  5. Miles D et al., ECC 2015, #1866.
  6. Herschbach et al., BJC 2004, 91: 504–511.
  7. O’Shaughnessy J et al., Cancer Res 2009, 69 (suppl): #207.
  8. Inbar MJ et al., ASCO JCO 2013, #1040.
  9. Kahàn Z et al., AACR 2013, #177.
  10. Lang I et al., Lancet Oncol 2013, 14: 125–133.
  11. Smith I et al., Ann Oncol 2011, 22: 595–602.
  12. Mentuccia L et al., ASCO JCO 2015, 33 (suppl), #549.
  13. E2100-Studie, Roche Data on File

Pharmaforum - (Multiples Myelom) Elotuzumab: Immunaktivierender Antikörper zugelassen

Dr. Yuri Sankawa/ Mit freundlicher Unterstützung von Bristol-Myers Squibb (S. 50-51)

 

  1. Lonial S et al. N Engl J Med 2015; 373: 621–31.
  2. Dimopoulos M et al. ELOQUENT-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma – 3-Year Safety and Efficacy Follow-up. Oral presentation, ASH 2015, Abstr. 27.
  3. Magarotto V et al. Leuk Lymphoma 2016; 57: 537–56.
  4. Robert-Koch-Institut. Krebs in Deutschland (2011/2012): Multiples Myelom. Online unter www.krebsdaten.de
  5. Fachinformation Empliciti® (Elotuzumab); Stand: Nov. 2015

Pharmaforum - (Datenupdate: Erster TKI für Patienten mit EGFR T790M mutationspositiven NSCLC) Mit Osimertinib Resistenz überwinden

Dr. Susanne Heinzl/ Mit freundlicher Unterstützung von AstraZeneca (S. 52)

 

  1. Szumera-Cie?kiewicz A, et al. Int J Clin Exp Pathol 2013;6:2800–12.
  2. Yang J, et al. Osimertinib (AZD9291) in pre-treated patients with T790M-positive advanced NSCLC: updated Phase I and pooled Phase II results. ELCC 2016, Genf, Abstract LBA2_PgR. https://cslide.ctimeetingtech.com/library/esmo/browse/itinerary/5344/2016-04-14#2A9p057
  3. AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA). https://clinicaltrials.gov/ct2/show/NCT02296125?term=FLAURA&rank=1